Reporting of adverse events ONLY

Patients should always seek the advice of a doctor or pharmacist in case of adverse events.

If you wish to report an adverse event to ELC Group s.r.o., please find the contact information below:

+420 224 910 672

(from 09.00-17.30 CET)

+420 226 251 459

(non-stop 24/7)

To contact us about any other issue please call:

+420 22 491 0000or our regional offices.

Hlášení nežádoucích príhod

Pacienti by meli vždy požádat o radu svého lékare nebo lékárníka v prípade výskytu nežádoucích príhod.

Pokud chcete nahlásit nežádoucí príhodu spolecnosti ELC Group s r.o., prosím využijte kontaktních údaju níže:

+420 224 910 672

(09.00-17.30 CET)

+420 226 251 459

(non-stop 24/7)

Pro záležitosti, které se netýkaji farmakovigilance, kontaktujte prosím recepci:

+420 22 491 0000 nebo naše další pobočky.

Pharmacovigilance Requirements in US & EU

Date: 29.06.2021

Time: 11:00 CEST

Price: Free of Charge

On Tuesday 29th June, 2021, at 11:00 CEST (Central European Summer Time, UTC+ 2), ELC will be hosting a webinar providing an overview of Pharmacovigilance Requirements in US & EU .

The presenters will be Dr. Devang Patel, General Manager for Pharmacovigilance and Mr. Riaz Ali Khan, Business Development from ELC Group.

We are going to take you through the following topics:
1. PV Requirements in US & EU
2. Difference between PV requirements in US & EU
3. Setting up a Single System for PV in US & EU
4. Challenges & Approaches
5. Inspection Findings
6. Questions & Answers

Please note that the number of participants is limited.

To register, click here